Cetuximab or cisplatin as a radiosensitizer in locoregionally advanced head and neck cancer: recent results

被引：2
|
作者：
Bonner, James A. [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL 35249 USA
来源：
TRANSLATIONAL CANCER RESEARCH | 2016年 / 5卷 / 03期
关键词：
SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; INFUSION REACTIONS; NORTH-CAROLINA; RADIOTHERAPY; CHEMOTHERAPY;
D O I：
10.21037/tcr.2016.06.22
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：234 / 237
页数：4
相关论文
共 50 条
  • [1] Cisplatin as a radiosensitizer in the treatment of locally advanced head and neck cancer
    Altundag, O
    Altundag, K
    Morandi, P
    Hanrahan, E
    [J]. ORAL ONCOLOGY, 2005, 41 (04) : 435 - 435
  • [2] Concurrent Cetuximab and Radiation Therapy in Patients with Locoregionally Advanced Head and Neck Cancer
    Cheng, H. C.
    Ngan, R. K. C.
    Au, K. H.
    [J]. HONG KONG JOURNAL OF RADIOLOGY, 2012, 15 (01): : 29 - 35
  • [3] Cetuximab in the management of locoregionally advanced head and neck cancer: Expanding the treatment options?
    Bourhis, Jean
    Lefebvre, Jean-Louis
    Vermorken, Jan B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) : 1979 - 1989
  • [4] Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer
    Saraswathula, Anirudh
    Chen, Michelle M.
    Colevas, A. Dimitrios
    Divi, Vasu
    [J]. JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2019, 145 (12) : 1160 - 1167
  • [5] Duration of mucositis and dysphagia following radiotherapy (+cetuximab) for locoregionally advanced head and neck cancer
    Bonner, J. A.
    Harari, P. M.
    Giralt, J.
    Raben, D.
    Jassem, J.
    Azarnia, N.
    Spencer, S. A.
    Rowinsky, E. K.
    Amellal, N.
    Baselga, J. L.
    Ang, K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (02): : S137 - S137
  • [6] Treatment Considerations for Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
    Kim, Sangwoo S.
    Liu, Hannah C.
    Mell, Loren K.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (03) : 147 - 161
  • [7] Phase III evaluation of radiation with and without cetuximab for locoregionally advanced head and neck cancer
    Bonner, JA
    Giralt, J
    Harari, PM
    Jones, C
    Cohen, R
    Sur, RK
    Raben, D
    Kies, MS
    Azarnia, N
    Molloy, PT
    Ang, KK
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S147 - S148
  • [8] Treatment Considerations for Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
    Sangwoo S. Kim
    Hannah C. Liu
    Loren K. Mell
    [J]. Current Treatment Options in Oncology, 2023, 24 : 147 - 161
  • [9] Induction docetaxel, cisplatin, and cetuximab (TPE) followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck entice (HNC): Mature results with HPV analysis.
    Ferris, R. L.
    Heron, D. E.
    Kim, S.
    Gibson, M. K.
    Posluszny, D.
    Seethala, R. R.
    Gooding, W. E.
    Johnson, J. T.
    Grandis, J. R.
    Argiris, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Radiotherapy with Durvalumab vs. Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer and a Contraindication to Cisplatin: Phase II Results of NRG-HN004
    Mell, L. K.
    Torres-Saavedra, P.
    Wong, S.
    Chang, S.
    Kish, J. A.
    Minn, A. J., III
    Jordan, R.
    Liu, T.
    Truong, M. T.
    Winquist, E.
    Wise-Draper, T.
    Rodriguez, C. P.
    Musaddiq, A.
    Beadle, B. M.
    Henson, C.
    Narayan, S.
    Spencer, S. A.
    Harris, J.
    Yom, S. S.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (05): : 1058 - 1058
12345